PT2935312T - Péptidos enquanto agonistas da oxitocina - Google Patents

Péptidos enquanto agonistas da oxitocina

Info

Publication number: PT2935312T
Authority: PT; Portugal
Prior art keywords: peptides; oxytocin agonists; oxytocin; agonists
Prior art date: 2012-12-21

Application number

PT13814079T

Other languages

English (en)

Inventor

Bissantz Caterina

Grundschober Christophe

Bleicher Konrad

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-21

Filing date

2013-12-17

Publication date

2018-10-26

2013-12-17 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2018-10-26 Publication of PT2935312T publication Critical patent/PT2935312T/pt

Links

102400000050 Oxytocin Human genes 0.000 title 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title 1
101800000989 Oxytocin Proteins 0.000 title 1
239000000556 agonist Substances 0.000 title 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
229960001723 oxytocin Drugs 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Psychiatry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Addiction (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT13814079T 2012-12-21 2013-12-17 Péptidos enquanto agonistas da oxitocina PT2935312T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12199012		2012-12-21

Publications (1)

Publication Number	Publication Date
PT2935312T true PT2935312T (pt)	2018-10-26

Family

ID=47471593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT13814079T PT2935312T (pt)	2012-12-21	2013-12-17	Péptidos enquanto agonistas da oxitocina

Country Status (33)

Country	Link
US (1)	US9868766B2 (pt)
EP (1)	EP2935312B1 (pt)
JP (1)	JP6067878B2 (pt)
KR (1)	KR101819804B1 (pt)
CN (1)	CN104870466B (pt)
AR (1)	AR094225A1 (pt)
AU (1)	AU2013363768B2 (pt)
BR (1)	BR112015014010A2 (pt)
CA (1)	CA2895150C (pt)
CL (1)	CL2015001724A1 (pt)
CR (1)	CR20150271A (pt)
DK (1)	DK2935312T3 (pt)
EA (1)	EA026687B1 (pt)
ES (1)	ES2690317T3 (pt)
HR (1)	HRP20181569T1 (pt)
HU (1)	HUE039848T2 (pt)
IL (1)	IL239519A (pt)
LT (1)	LT2935312T (pt)
MA (1)	MA38272A1 (pt)
MX (1)	MX358684B (pt)
MY (1)	MY176398A (pt)
NZ (1)	NZ708175A (pt)
PE (1)	PE20151446A1 (pt)
PH (1)	PH12015501145A1 (pt)
PL (1)	PL2935312T3 (pt)
PT (1)	PT2935312T (pt)
RS (1)	RS57690B1 (pt)
SG (1)	SG11201504883PA (pt)
SI (1)	SI2935312T1 (pt)
TW (1)	TWI558726B (pt)
UA (1)	UA119034C2 (pt)
WO (1)	WO2014095773A1 (pt)
ZA (1)	ZA201504186B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10039777B2 (en)	2012-03-20	2018-08-07	Neuro-Lm Sas	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
UA111305C2 (uk)	2012-12-21	2016-04-11	Пфайзер Інк.	Конденсовані лактами арилу та гетероарилу
GEP201706757B (en)	2012-12-21	2017-10-25	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
EP2935312B1 (en)	2012-12-21	2018-08-08	F.Hoffmann-La Roche Ag	Peptides as oxytocin agonists
KR102116107B1 (ko)	2013-12-30	2020-05-28	삼성디스플레이 주식회사	표시 장치
ES2748434T3 (es)	2014-01-10	2020-03-16	Univ Cornell	Dipéptidos como inhibidores de inmunoproteasomas humanos
AU2015270723A1 (en)	2014-06-03	2016-11-17	F. Hoffmann-La Roche Ag	Peptides as oxytocin agonists
EP3157915B1 (en)	2014-06-17	2019-02-27	Pfizer Inc	Substituted dihydroisoquinolinone compounds
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
HRP20181916T1 (hr) *	2014-08-07	2019-01-11	F. Hoffmann - La Roche Ag	Postupci pripreme oksitocinskih analoga
EP3193904B1 (en) *	2014-08-18	2025-10-01	Cornell University	Dipeptidomimetics as inhibitors of human immunoproteasomes
ES2970059T3 (es) *	2014-09-19	2024-05-24	Ferring Bv	Método de tratamiento del síndrome de Prader-Willi
KR102764027B1 (ko)	2015-10-15	2025-02-07	코넬 유니버시티	프로테아좀 억제제 및 이의 용도
EP3694605A4 (en)	2017-10-11	2021-10-27	Cornell University	PEPTIDOMIMETIC PROTEASOME INHIBITORS
EP3852724A4 (en)	2018-09-20	2022-07-06	Levo Therapeutics, Inc.	CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
TW202031283A (zh)	2018-09-20	2020-09-01	馬克Ｃ曼寧	穩定卡貝縮宮素鼻內製劑
WO2021126990A1 (en) *	2019-12-16	2021-06-24	The Scripps Research Institute	Oxytocin derivatives with improved properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2260053B1 (en)	2008-03-31	2014-05-14	Ferring BV	Oxytocin analogues
TWI463990B (zh) *	2009-09-21	2014-12-11	Ferring Bv	催產素受體促進劑
EP2482835B1 (en) *	2009-10-01	2014-07-02	The University Of Sydney	Therapy and prevention of problem drinking
EP2935312B1 (en)	2012-12-21	2018-08-08	F.Hoffmann-La Roche Ag	Peptides as oxytocin agonists

2013
- 2013-12-17 EP EP13814079.3A patent/EP2935312B1/en not_active Not-in-force
- 2013-12-17 EA EA201591078A patent/EA026687B1/ru not_active IP Right Cessation
- 2013-12-17 KR KR1020157016376A patent/KR101819804B1/ko not_active Expired - Fee Related
- 2013-12-17 PL PL13814079T patent/PL2935312T3/pl unknown
- 2013-12-17 ES ES13814079.3T patent/ES2690317T3/es active Active
- 2013-12-17 HR HRP20181569TT patent/HRP20181569T1/hr unknown
- 2013-12-17 AU AU2013363768A patent/AU2013363768B2/en not_active Ceased
- 2013-12-17 SG SG11201504883PA patent/SG11201504883PA/en unknown
- 2013-12-17 DK DK13814079.3T patent/DK2935312T3/en active
- 2013-12-17 MA MA38272A patent/MA38272A1/fr unknown
- 2013-12-17 CA CA2895150A patent/CA2895150C/en not_active Expired - Fee Related
- 2013-12-17 SI SI201331190T patent/SI2935312T1/sl unknown
- 2013-12-17 NZ NZ708175A patent/NZ708175A/en not_active IP Right Cessation
- 2013-12-17 BR BR112015014010A patent/BR112015014010A2/pt not_active IP Right Cessation
- 2013-12-17 LT LTEP13814079.3T patent/LT2935312T/lt unknown
- 2013-12-17 JP JP2015548420A patent/JP6067878B2/ja not_active Expired - Fee Related
- 2013-12-17 UA UAA201506906A patent/UA119034C2/uk unknown
- 2013-12-17 MX MX2015007365A patent/MX358684B/es active IP Right Grant
- 2013-12-17 RS RS20181124A patent/RS57690B1/sr unknown
- 2013-12-17 PT PT13814079T patent/PT2935312T/pt unknown
- 2013-12-17 MY MYPI2015001585A patent/MY176398A/en unknown
- 2013-12-17 HU HUE13814079A patent/HUE039848T2/hu unknown
- 2013-12-17 WO PCT/EP2013/076783 patent/WO2014095773A1/en not_active Ceased
- 2013-12-17 PE PE2015001058A patent/PE20151446A1/es unknown
- 2013-12-17 CN CN201380066617.7A patent/CN104870466B/zh not_active Expired - Fee Related
- 2013-12-20 AR ARP130104962A patent/AR094225A1/es unknown
- 2013-12-20 TW TW102147655A patent/TWI558726B/zh not_active IP Right Cessation
2015
- 2015-05-21 CR CR20150271A patent/CR20150271A/es unknown
- 2015-05-22 PH PH12015501145A patent/PH12015501145A1/en unknown
- 2015-06-10 ZA ZA2015/04186A patent/ZA201504186B/en unknown
- 2015-06-18 IL IL239519A patent/IL239519A/en active IP Right Grant
- 2015-06-18 US US14/743,009 patent/US9868766B2/en not_active Expired - Fee Related
- 2015-06-18 CL CL2015001724A patent/CL2015001724A1/es unknown

Also Published As

Publication number	Publication date
CA2895150A1 (en)	2014-06-26
EA201591078A1 (ru)	2015-10-30
PH12015501145B1 (en)	2015-08-10
PH12015501145A1 (en)	2015-08-10
NZ708175A (en)	2020-06-26
MA38272A1 (fr)	2017-07-31
TWI558726B (zh)	2016-11-21
AU2013363768B2 (en)	2016-02-04
CL2015001724A1 (es)	2015-10-16
BR112015014010A2 (pt)	2017-07-11
KR101819804B1 (ko)	2018-01-17
CN104870466B (zh)	2018-05-18
UA119034C2 (uk)	2019-04-25
CA2895150C (en)	2019-11-26
PE20151446A1 (es)	2015-09-28
LT2935312T (lt)	2018-10-25
SI2935312T1 (sl)	2018-11-30
KR20150085845A (ko)	2015-07-24
EP2935312A1 (en)	2015-10-28
JP2016503044A (ja)	2016-02-01
EP2935312B1 (en)	2018-08-08
WO2014095773A1 (en)	2014-06-26
ES2690317T3 (es)	2018-11-20
AU2013363768A1 (en)	2015-06-04
AR094225A1 (es)	2015-07-22
ZA201504186B (en)	2016-04-28
IL239519A (en)	2017-06-29
PL2935312T3 (pl)	2018-12-31
IL239519A0 (en)	2015-08-31
JP6067878B2 (ja)	2017-01-25
US20150284434A1 (en)	2015-10-08
DK2935312T3 (en)	2018-10-22
MX358684B (es)	2018-08-31
CN104870466A (zh)	2015-08-26
MX2015007365A (es)	2015-10-14
EA026687B1 (ru)	2017-05-31
MY176398A (en)	2020-08-05
HUE039848T2 (hu)	2019-02-28
US9868766B2 (en)	2018-01-16
RS57690B1 (sr)	2018-11-30
TW201429994A (zh)	2014-08-01
HK1208477A1 (en)	2016-03-04
SG11201504883PA (en)	2015-07-30
HRP20181569T1 (hr)	2018-11-30
CR20150271A (es)	2015-08-28

Publication	Publication Date	Title
IL291571A (en)	2022-05-01	cx3cr1 binding polypeptides
IL239519A0 (en)	2015-08-31	Peptides as oxytocin agonists
EP2857033A4 (en)	2016-03-30	PEPTIDE WITH SKIN PERMEATION
GB201220474D0 (en)	2012-12-26	Polypeptides
GB201218813D0 (en)	2012-12-05	Antimicrobial peptides
IL237636A0 (en)	2015-04-30	new uses
ZA201503127B (en)	2016-10-26	Peptides
GB201200555D0 (en)	2012-02-29	Peptide
GB201220119D0 (en)	2012-12-26	Vector
SG11201502356YA (en)	2015-05-28	Compressor
GB201204868D0 (en)	2012-05-02	Peptides
GB201220899D0 (en)	2013-01-02	CD44v6-derived pegylated peptides
GB201205795D0 (en)	2012-05-16	Vector
GB201201720D0 (en)	2012-03-14	Novel combinations
GB2500883B (en)	2015-05-27	Improved saw-horse
GB201223114D0 (en)	2013-02-06	Novel peptide
HUE036243T2 (hu)	2018-06-28	PSF1-származék peptid
IL235840A0 (en)	2015-01-29	Alternaria peptides
GB201214413D0 (en)	2012-09-26	Festivalstand (festistand)
GB201213672D0 (en)	2012-09-12	Protein
GB201304493D0 (en)	2013-04-24	Not published
GB201220328D0 (en)	2012-12-26	Peptides
GB201211740D0 (en)	2012-08-15	Peptides
GB201207895D0 (en)	2012-06-20	Peptides
GB201200509D0 (en)	2012-02-22	Peptides